Global Artificial Pancreas Device System (APDS) Market: Rapid Expansion Projected for 2024
Eating habits of type 1 diabetes patients is highly curtailed, complemented by regular administration of insulin. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year. Advancements in research and technology has led to commercialization of easy-to-us insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems mentioned above.
Eating habits of type 1 diabetes patients is highly curtailed, complemented by regular administration of insulin. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year. Advancements in research and technology has led to commercialization of easy-to-us insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems mentioned above.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Global</strong> <strong>Artificial</strong> <strong>Pancreas</strong> <strong>Device</strong> <strong>System</strong> (APDS)<br />
<strong>Market</strong>: <strong>Rapid</strong> <strong>Expansion</strong> <strong>Projected</strong> <strong>for</strong> <strong>2024</strong><br />
<strong>Global</strong> <strong>Artificial</strong> <strong>Pancreas</strong> <strong>Device</strong> <strong>System</strong> (APDS) <strong>Market</strong>, By Technology<br />
(Threshold Suspended <strong>Device</strong> <strong>System</strong>s, Treat to Range/Control to Range<br />
(TTR/CTR), Treat to Target/ Control to Target (TTR/CTT)), Distribution Channel<br />
(E-commerce, Standalone Retail Shops, Hospitals), End User (Type 1 Diabetic<br />
Patients, Type 2 Diabetic Patients), and Geography - Trends, Analysis and<br />
Forecast till <strong>2024</strong><br />
Eating habits of type 1 diabetes patients is highly curtailed, complemented by regular administration of<br />
insulin. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year.<br />
Advancements in research and technology has led to commercialization of easy-to-us insulin delivery<br />
systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin<br />
has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems<br />
mentioned above.<br />
Request For a Sample Copy of This Business Report @<br />
https://www.coherentmarketinsights.com/insight/request-sample/79<br />
Moreover, these systems offer the convenience to self-administer insulin at home. An artificial pancreas<br />
is a novel concept that promises to revolutionize the entire diabetes market. The system automatically<br />
detects glucose level in patient’s blood or plasma and accordingly administers the necessary dosage of<br />
insulin. Medtronic’s MiniMed 670G is one such wearable artificial pancreas. The system is automated
to monitor glucose levels and deliver insulin through an insulin pump attached to the system. The<br />
artificial pancreas system comprises a transmitter, sensor, and insulin pump. This helps in continuous<br />
monitoring and diabetes management at ease.<br />
<strong>Market</strong> Dynamics<br />
The artificial pancreas device system (APDS) market growth would be mainly driven by increasing<br />
adoption of the highly useful systems the large base of diabetes type 1 patients, further supplemented<br />
by ever increasing incidence of type 1 diabetes. According to the World Health Organization (WHO),<br />
number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014.<br />
According to Juvenile Diabetes Research Foundation (JDRF), there were around 1.5 million type 1<br />
diabetics worldwide in 2015. JDRF funds research in diabetes 1 and the non-profit organization<br />
expected the first artificial pancreas to be commercialized in 2017. According to the Center <strong>for</strong> Disease<br />
Control and Prevention (CDC), type 1 diabetes accounts <strong>for</strong> around 5% of the total diagnosed diabetes<br />
cases in adults in the U.S. Developed regions are expected to dominate the artificial pancreas device<br />
system (APDS) market size, as these regions are early adopters of disruptive technologies.<br />
Key companies covered as a part of this study include Medtronic, Medtrum, Tandem Diabetes Care,<br />
Inc., Johnson & Johnson, Beta Bionics, Bigfoot Biomedical, and Insulet Corporation.<br />
Technological advancements to drive growth of the global artificial pancreas device system<br />
(APDS) market<br />
In 2016, the U.S. FDA approved a hybrid closed-loop artificial pancreas device system (APDS)<br />
MiniMed 670G which is an automated system. The continuous glucose monitor in the system<br />
automatically sends signals to the insulin pump to deliver insulin when the glucose level in body goes<br />
beyond the acceptable limit. Thus, there is no need <strong>for</strong> the user to stimulate the release of insulin every<br />
time the glucose level is abnormal. This provide the user freedom to per<strong>for</strong>m his/her daily activities.<br />
Such advancement in T1D management is expected to be highly preferred by the users and medical<br />
community, leading to higher advocacy to use this device especially among the patient group using<br />
insulin pumps. Moreover, in mid-2018, a study will test a bihormonal “bionic pancreas” system at the<br />
Massachusetts General Hospital (Boston) and Boston University. This would further fuel the <strong>Global</strong><br />
<strong>Artificial</strong> <strong>Pancreas</strong> <strong>Device</strong> <strong>System</strong> (APDS) <strong>Market</strong> growth and attract more investments.
About Coherent <strong>Market</strong> Insights:<br />
Coherent <strong>Market</strong> Insights is a prominent market research and consulting firm offering action-ready<br />
syndicated research reports, custom market analysis, consulting services, and competitive analysis<br />
through various recommendations related to emerging market trends, technologies, and potential<br />
absolute dollar opportunity.<br />
Contact Us:<br />
Mr. Shah<br />
Coherent <strong>Market</strong> Insights<br />
1001 4th Ave, #3200<br />
Seattle, WA 98154<br />
Tel: +1–206–701–6702<br />
Email: sales@coherentmarketinsights.com
Change language